CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Total revenue	$ 18,720	$ 31,249
Costs and expenses:
Cost of revenue	2,792	3,423
Research and development	33,586	98,384
General and administrative	22,203	32,412
Licensing	12,666	14,658
Revaluation of contingent consideration	2,500	(26,900)
In-process research and development	86,905	6,629
Total costs and expenses	160,652	128,606
Loss from operations	(141,932)	(97,357)
Other income:
Interest income	7,953	8,509
Non-cash royalty income	1,914
Total other income	9,867	8,509
Loss before income taxes	(132,065)	(88,848)
Income tax benefit		(367)
Net loss	$ (132,065)	$ (88,481)
Net loss per share, basic	$ (1.71)	$ (1.27)
Net loss per share, diluted	$ (1.71)	$ (1.27)
Weighted average common shares outstanding, basic	77,296,665	69,808,855
Weighted average common shares outstanding, diluted	77,296,665	69,808,855
Other comprehensive income:
Unrealized gain on marketable securities, net of tax of $0	$ 203	$ 791
Total other comprehensive income	203	791
Comprehensive loss	(131,862)	(87,690)
Contract research
Revenues:
Total revenue	2,541	3,035
Licensing
Revenues:
Total revenue	$ 16,179	$ 28,214